Holen Sie sich die Stockscreener-App
1.03
5.07%
-0.055
Schlusskurs vom Vortag:
$1.085
Offen:
$1.03
24-Stunden-Volumen:
415.84K
Relative Volume:
1.17
Marktkapitalisierung:
$70.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-60.36M
KGV:
-0.2344
EPS:
-4.394
Netto-Cashflow:
$-15.05M
1W Leistung:
-18.58%
1M Leistung:
-10.43%
6M Leistung:
-76.48%
1J Leistung:
-64.48%
1-Tages-Spanne:
$0.97
$1.15
1-Wochen-Bereich:
$0.97
$1.3495
52-Wochen-Spanne:
$0.97
$6.35
Zura Bio Ltd Stock (ZURA) Company Profile
Firmenname
Zura Bio Ltd
Sektor
Branche
Telefon
858-247-0520
Adresse
4225 EXECUTIVE SQUARE, LA JOLLA
Vergleichen Sie ZURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
1.03 | 70.43M | 0 | -60.36M | -15.05M | -4.394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-04 | Eingeleitet | Leerink Partners | Outperform |
| 2024-09-05 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-05-03 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-10 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2023-08-25 | Eingeleitet | Oppenheimer | Outperform |
| 2023-06-22 | Eingeleitet | Guggenheim | Buy |
| 2023-06-14 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-05-24 | Eingeleitet | Raymond James | Strong Buy |
Alle ansehen
Zura Bio Ltd Aktie (ZURA) Neueste Nachrichten
H.C. Wainwright cuts Zura Bio stock target to $3, keeps neutral rating - Investing.com Australia
ZURA stock touches 52-week low at $1.07 amid market challenges - Investing.com
Insiders' US$1.01m Investments In Red Following Zura Bio's US$21m Dip In Market Value - simplywall.st
Cantor Fitzgerald Forecasts Weaker Earnings for Zura Bio - Defense World
Zura Bio (NASDAQ:ZURA) Price Target Lowered to $10.00 at Chardan Capital - Defense World
Zura Bio Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Chardan cuts Zura Bio stock target to $10, keeps buy rating By Investing.com - Investing.com South Africa
Chardan cuts Zura Bio stock target to $10, keeps buy rating - Investing.com Australia
Guggenheim maintains Zura Bio stock buy rating, $15 target By Investing.com - Investing.com Australia
Guggenheim maintains Zura Bio stock buy rating, $15 target - Investing.com
Leerink maintains $12 target on Zura Bio stock post-earnings By Investing.com - Investing.com Australia
Leerink maintains $12 target on Zura Bio stock post-earnings - Investing.com
Zura Bio Ltd expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates - Yahoo Finance
Zura Bio (ZURA) Projected to Post Quarterly Earnings on Thursday - Defense World
Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Consensus Price Target from Analysts - Defense World
Rhumbline Advisers Has $94,000 Stock Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Zura Bio to Present at the Leerink Partners Global Healthcare Conference - Yahoo Finance
Can Zura Bio's Novel Dual-Pathway Antibodies Transform Autoimmune Treatment? Key Updates Coming - Stock Titan
Analysts Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $15.80 - Defense World
Zura Bio Limited (NASDAQ:ZURA) Shares Purchased by SG Americas Securities LLC - Defense World
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - ADVFN
ZURA stock touches 52-week low at $1.44 amid market shifts - Investing.com Nigeria
ZURA stock touches 52-week low at $1.44 amid market shifts By Investing.com - Investing.com South Africa
After losing 43% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain - Simply Wall St
Zura Bio (NASDAQ:ZURA) vs. Aptose Biosciences (NASDAQ:APTO) Critical Contrast - Defense World
Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA) - MSN
Cantor Fitzgerald Predicts Zura Bio FY2025 Earnings - MarketBeat
We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth - Yahoo Finance
Barclays PLC Purchases 56,757 Shares of Zura Bio Limited (NASDAQ:ZURA) - Defense World
ZURA stock touches 52-week low at $1.97 amid market shifts - Investing.com Canada
Corporate Overview January 2025 Advancing Dual Pathway Biologic Candidates: Addressing Unmet Needs in Autoimmune and Inflammatory Diseases - Marketscreener.com
Zura Bio Highlights Strategic Goals and Clinical Advances - TipRanks
Barclays PLC Raises Stock Holdings in Zura Bio Limited (NASDAQ:ZURA) - Defense World
State Street Corp Increases Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Reversal Of Fortune For Zura Bio Insiders Who Made A US$1.01m Purchase - Simply Wall St
Zura Bio’s (ZURA) Neutral Rating Reaffirmed at HC Wainwright - Defense World
Zura Bio shares outlook positive as Phase 2 TibuSURE study evaluates key SSc complications - Investing.com India
Zura Bio begins Phase 2 study for systemic sclerosis treatment By Investing.com - Investing.com South Africa
Zura Bio initiates Phase II systemic sclerosis treatment trial - Yahoo Finance
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis - Quantisnow
17,442 Shares in Zura Bio Limited (NASDAQ:ZURA) Acquired by The Manufacturers Life Insurance Company - Defense World
Zura Bio FY2025 EPS Forecast Increased by Leerink Partnrs - Defense World
Zura Bio FY2025 EPS Forecast Boosted by Leerink Partnrs - MarketBeat
Finanzdaten der Zura Bio Ltd-Aktie (ZURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):